Request Demo
Last update 25 Apr 2026
TAK-020
Last update 25 Apr 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms TAK 020, TAK020 |
Target |
Action inhibitors |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC18H17N5O3 |
InChIKeyHIMUHMBGRATXMK-LBPRGKRZSA-N |
CAS Registry1627603-21-7 |
Related
2
Clinical Trials associated with TAK-020NCT02723201
A Randomized, Open Label Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of a Single Dose of Various Test Solid Formulations of TAK-020 Compared With a Single Dose of Reference Oral Solution and to Evaluate the Food Effect and Potentially the Dose Proportionality of the Optimal Solid Dose Formulation
NCT02413255
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-020 in Healthy Volunteers
100 Clinical Results associated with TAK-020
Login to view more data
100 Translational Medicine associated with TAK-020
Login to view more data
100 Patents (Medical) associated with TAK-020
Login to view more data
3
Literatures (Medical) associated with TAK-02011 Nov 2021Journal of medicinal chemistryQ1 · MEDICINE
Correction to “Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design”
Q1 · MEDICINE
Author: Dougan, Douglas R ; Smith, Christopher R ; Sabat, Mark ; Balakrishna, Deepika ; Knight, Beverly ; Taylor, Ewan R ; McConn, Donavon ; Lawson, J. David ; Madakamutil, Loui ; Hixon, Mark ; Wang, Haixia ; Wyrick, Corey ; Scorah, Nicholas ; Halkowycz, Petro ; Ermolieff, Jacques ; Vu, Phong
ADVERTISEMENT RETURN TO ISSUEPREVAddition/CorrectionNEXTORIGINAL ARTICLEThis notice is a correctionCorrection to "Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design"Mark Sabat*Mark SabatTakeda California, 9625 Towne Centre Drive, San Diego, California 92121, United StatesMore by Mark Sabathttps://orcid.org/0000-0001-8916-1203, Douglas R DouganDouglas R DouganTakeda California, 9625 Towne Centre Drive, San Diego, California 92121, United StatesMore by Douglas R Dougan, Jacques ErmolieffJacques ErmolieffTango Therapeutics, 100 Binney Street, Suite 700, Cambridge, Massachusetts 02142, United StatesMore by Jacques Ermolieff, Petro HalkowyczPetro HalkowyczTakeda California, 9625 Towne Centre Drive, San Diego, California 92121, United StatesMore by Petro Halkowycz, Beverly KnightBeverly KnightPfizer, 10777 Science Center Drive, San Diego, California 92121, United StatesMore by Beverly Knight, J. David LawsonJ. David LawsonMirati Therapeutics, Inc., 9393 Towne Centre Drive #200, San Diego, California 92121, United StatesMore by J. David Lawson, Nicholas ScorahNicholas ScorahTakeda California, 9625 Towne Centre Drive, San Diego, California 92121, United StatesMore by Nicholas Scorah, Christopher R SmithChristopher R SmithMirati Therapeutics, Inc., 9393 Towne Centre Drive #200, San Diego, California 92121, United StatesMore by Christopher R Smith, Ewan R TaylorEwan R TaylorTakeda California, 9625 Towne Centre Drive, San Diego, California 92121, United StatesMore by Ewan R Taylor, Phong VuPhong VuTakeda California, 9625 Towne Centre Drive, San Diego, California 92121, United StatesMore by Phong Vu, Corey WyrickCorey WyrickTakeda California, 9625 Towne Centre Drive, San Diego, California 92121, United StatesMore by Corey Wyrick, Haixia WangHaixia WangTakeda California, 9625 Towne Centre Drive, San Diego, California 92121, United StatesMore by Haixia Wang, Deepika BalakrishnaDeepika BalakrishnaTakeda California, 9625 Towne Centre Drive, San Diego, California 92121, United StatesMore by Deepika Balakrishna, Mark HixonMark HixonVeriSIM Life, 1 Sansome Street Suite 3500 San Francisco, California 94104, United StatesMore by Mark Hixon, Loui MadakamutilLoui MadakamutilInvivoscribe Therapeutics, Inc., 10222 Barnes Canyon Road, Building 1, San Diego, California 92121, United StatesMore by Loui Madakamutil, and Donavon McConnDonavon McConnTakeda California, 9625 Towne Centre Drive, San Diego, California 92121, United StatesMore by Donavon McConnCite this: J. Med. Chem. 2021, 64, 21, 16318Publication Date (Web):October 28, 2021Publication History Published online28 October 2021Published inissue 11 November 2021https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01685https://doi.org/10.1021/acs.jmedchem.1c01685correctionACS PublicationsCopyright © 2021 American Chemical Society. This publication is available under these Terms of Use. Request reuse permissions This publication is free to access through this site. Learn MoreArticle Views1281Altmetric-Citations-LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail PDF (381 KB) Get e-Alertsclose Get e-Alerts
09 Sep 2021Journal of medicinal chemistryQ1 · MEDICINE
Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design
Q1 · MEDICINE
Article
Author: Smith, Christopher R ; Dougan, Douglas R ; Wang, Haixia ; Balakrishna, Deepika ; Vu, Phong ; Sabat, Mark ; McConn, Donavon ; Knight, Beverly ; Lawson, J. David ; Madakamutil, Loui ; Scorah, Nicholas ; Wyrick, Corey ; Hixon, Mark ; Taylor, Ewan R
This publication details the successful use of FBDD (fragment-based drug discovery) principles in the invention of a novel covalent Bruton's tyrosine kinase inhibitor, which ultimately became the Takeda Pharmaceuticals clinical candidate TAK-020. Described herein are the discovery of the fragment 5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-one, the subsequent optimization of this hit molecule to the candidate, and synthesis and performance in pharmacodynamic and efficacy models along with direct biophysical comparison of TAK-020 with other clinical-level assets and the marketed drug Ibrutinib.
Crystals
Pharmaceutical Cocrystal Development of TAK-020 with Enhanced Oral Absorption
Author: Yamamoto, Mitsuo ; Hohokabe, Miyuki ; Karashima, Masatoshi ; Kimoto, Kouya ; Takeda, Junpei ; Ikeda, Yukihiro ; Yamamoto, Katsuhiko
The objective of this study was to improve the solubility of poorly water-soluble drugs by pharmaceutical cocrystal engineering techniques and select the best pharmaceutical forms with high solubility and solubilized formulations for progress from the early discovery stage toward the clinical stage. Several pharmaceutical cocrystals of TAK-020, a Bruton tyrosine kinase inhibitor, were newly discovered in the screening based on the solid grinding method and the slurry method, considering thermodynamic factors that dominate cocrystal formation. TAK-020/gentisic acid cocrystal (TAK-020/GA CC) was selected based on a physicochemical property of enhanced dissolution rate. TAK-020/GA CC was proven to be a reliable cocrystal formation with a definitive stoichiometric ratio by a variety of analytical techniques—pKa calculation, solid-state nuclear magnetic resonance, and single X-ray structure analysis from the view of regulation. Furthermore, its absorption was remarkable and beyond those achieved in currently existing solubilized formulation techniques, such as nanocrystal, amorphous solid dispersion, and lipid-based formulation, in dog pharmacokinetic studies. TAK-020/GA CC was the best drug form, which might lead to good pharmacological effects with regard to enhanced absorption and development by physicochemical characterization. Through the trials of solid-state optimization from early drug discovery to pharmaceutical drug development, the cocrystals can be an effective option for achieving solubilization applicable in the pharmaceutical industry.
100 Deals associated with TAK-020
Login to view more data
R&D Status
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | - | - | hcqeahdorw(qdivmyxdal) = Abdominal distension, upper abdominal pain, nausea, and headache were reported as drug-related TEAEs in 3 subjects in the TAK-020 group. In 4 subjects (11.1%) these were considered drug-related and included nausea, diarrhea, dizziness and headache. qaodlatfot (qdyegwaalt ) View more | Positive | 13 Jun 2018 | ||
Placebo | |||||||
Phase 1 | - | 25 | (Part 1: TAK-020 17.5 mg OS) | lsiguzxkov(xfbzxerirw) = lycgpadrbt gqpstpvtfl (hwuzvddlky, 35.0658) View more | - | 13 Apr 2018 | |
(Part 1: TAK-020 17.5 mg CCT) | lsiguzxkov(xfbzxerirw) = uoxbtnujtd gqpstpvtfl (hwuzvddlky, 26.4189) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free